Cynata Therapeutics Ltd CYYNF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.07
- Day Range
- $0.11–0.11
- 52-Week Range
- $0.07–0.11
- Bid/Ask
- $0.00 / $0.30
- Market Cap
- $19.76 Mil
- Volume/Avg
- 220 / 220
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- https://www.cynata.com
Valuation
|
Metric
|
CYYNF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.36 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CYYNF
|
|---|---|
Quick Ratio | 9.51 |
Current Ratio | 9.70 |
Interest Coverage | — |
Quick Ratio
CYYNF
Profitability
|
Metric
|
CYYNF
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
CYYNF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Clszxsxnh | Xml | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Njgprswvt | Wdtrm | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kskhmrg | Nzvsdn | $103.7 Bil | |
MRNA
| Moderna Inc | Xzbtkcxc | Jbw | $47.9 Bil | |
ARGX
| argenx SE ADR | Qfkvjzgp | Hhfbs | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Fdvpfckm | Bxxh | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Chgbxnpg | Fgbyx | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Scwwxkg | Sbzkcdz | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vlggcbswmq | Bbntjc | $12.8 Bil | |
INCY
| Incyte Corp | Xlynhdvs | Glpbvd | $12.1 Bil |